Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
Operas
283
Oratorios
18
Drama
14
Oratorios (Música)
13
Musical settings
10
Música - Siglo XIX
10
Songs and music
10
Música vocal sacra
9
Ballets
7
Libretos
6
Cantatas, Secular
5
Música
5
Música de la pasión
5
Zarzuelas
5
Música orquestal
4
Coros sacros (Voces mixtas) con orquesta
3
Extractos
3
Música barroca
3
Passion music
3
Suites (Orchestra)
3
Suites (Orquesta)
3
Ópera
3
Cantatas seglares
2
Excerpts
2
Folk dance music
2
Historia
2
Librettos
2
Mascaradas (Teatro con música)
2
Misa (Música)
2
Música Incidental
2
-
1por Subbiah, Vivek, Gainor, Justin F., Oxnard, Geoffrey R., Tan, Daniel S.W., Owen, Dwight H., Cho, Byoung Chul, Loong, Herbert H., McCoach, Caroline E., Weiss, Jared, Kim, Yu Jung, Bazhenova, Lyudmila, Park, Keunchil, Daga, Haruko, Besse, Benjamin, Gautschi, Oliver, Rolfo, Christian, Zhu, Edward Y., Kherani, Jennifer F., Huang, Xin, Kang, Suhyun, Drilon, Alexander“…PATIENTS AND METHODS: In the global phase 1/2 LIBRETTO-001 trial (NCT03157128) in advanced RET-altered solid tumors, selpercatinib was dosed orally (160 mg twice every day) in 28-day cycles. …”
Publicado 2021
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2por Wirth, Lori J, Brose, Marcia S, Elisei, Rossella, Capdevila, Jaume, Hoff, Ana O, Hu, Mimi I, Tahara, Makoto, Robinson, Bruce, Gao, Ming, Xia, Meng, Maeda, Patricia, Sherman, Eric“…In the phase I/II trial, selpercatinib demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pre-treated and treatment-naive patients with RET-mutant medullary thyroid cancer (MTC). LIBRETTO-531 (NCT04211337) is a multicenter, open-label, randomized, controlled, phase III trial comparing selpercatinib to cabozantinib or vandetanib in patients with advanced/metastatic RET-mutant MTC. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
3por Rolfo, C., Hess, L.M., Jen, M.-H., Peterson, P., Li, X., Liu, H., Lai, Y., Sugihara, T., Kiiskinen, U., Vickers, A., Summers, Y.“…RESULTS: In first-line unadjusted analyses of the real-world control, ORR was 87.2% for LIBRETTO-001 versus 66.7% for those with RET-positive NSCLC (P = 0.06). …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
4
-
5
-
6por Zheng, Xiangqian, Ji, Qinghai, Sun, Yuping, Ge, Minghua, Zhang, Bin, Cheng, Ying, Lei, Shangtong, Shi, Feng, Guo, Ye, Li, Linfa, Chen, Lu, Shao, Jingxin, Zhang, Wanli, Gao, Ming“…PATIENTS AND METHODS: In the open-label, multi-center phase II LIBRETTO-321 (NCT04280081) study, Chinese patients with advanced solid tumors harboring RET alterations received selpercatinib 160 mg twice daily. …”
Publicado 2022
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19por Cheng, Ying, Huang, Dingzhi, Zhou, Jianying, Zhou, Chengzhi, Sun, Yuping, Wu, Lin, Guo, Ye, Jingxin, Shao, Zhang, Wanli, Lu, Shun“…PURPOSE: Selpercatinib, a highly selective, potent RET inhibitor with CNS activity, demonstrated sustained antitumor responses and intracranial activity in patients with RET-altered advanced non–small-cell lung cancer (NSCLC) in the global LIBRETTO-001 and Chinese LIBRETTO-321 trials. We report a prospective case series based on updated data from patients with brain metastases at baseline in LIBRETTO-321. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
20